Microglia are particularly plastic cells which can be shifted from their resting state by numerous factors and adopt distinct phenotypes. The cells are multifunctional, though their main role is probably maintenance of homeostasis. Resting cells are responsible for surveillance, whereas activation induces the cells to adopt neuroprotective or neurodetrimental roles, which are anti-inflammatory or pro-inflammatory respectively. The evidence indicates that activated cells with a pro-inflammatory phenotype predominate in neurodegenerative diseases and models of neurodegeneration and that this may significantly contribute to the deteriorating neuronal function. This question is considered in this review, in particular in the context of animal models of Alzheimer's disease (AD).
Introduction
The idea that microglia are 'the macrophages of the brain', although inaccurate, is useful when considering their phenotypes since there is a great deal more understanding of the biology of macrophages. However, while macrophages and microglia are cells of the myeloid lineage, microglia are derived from primitive macrophages in the yolk sac that migrate to the central nervous system (CNS) early in development (Ginhoux et al., 2010) . Therefore, a fundamental difference between the cells is that they encounter entirely diverse stimuli throughout life; for example, microglia are juxtaposed with cells that are electrically active, while macrophages are exposed to a wide variety of pathogens that, in the main, do not pass the blood brain barrier and therefore are generally not encountered by microglia.
Microglia, as sentinel cells in the brain, react to any stimulus that poses a potential threat to the brain. Indeed activation of glia, especially microglia, is fundamentally responsible for the inflammatory changes that characterize the brain following exposure to any insult. For example, ischemia, injury and infection are associated with rapid microglial activation and associated inflammatory changes, but these are designed to combat the effect of the insult and ultimately return the tissue to homeostasis. This acute reaction is therefore considered to be protective. In contrast, persistent microglial activation with the associated increase in expression of inflammatory cytokines and chemokines, accompanied by recruitment of peripheral cells into the brain, characterizes chronic neuroinflammation (Lynch, 2009 (Lynch, , 2010 . It has been known for many years that neuroinflammatory changes are a characteristic of, and persist in, the brain of aged individuals and a great deal of data suggests that neuroinflammation is one of the common features of several neurodegenerative diseases (Akiyama et al., 2000; Lynch, 2013) . As reviewed by several authors, microglial activation has been described in Alzheimer's disease (AD) (Fuller et al., 2009; Heneka and O'Banion, 2007; McGeer and McGeer, 2003 ), Parkinson's disease (PD) (Long-Smith et al., 2009; McGeer and McGeer, 2008; Ouchi et al., 2009 ) and indeed there is epidemiological evidence indicating that anti-inflammatory agents reduce the risk of AD (Launer, 2003; Rich et al., 1995; Vlad et al., 2008) and PD (Chen et al., 2005; Esposito et al., 2007) .
It has become increasingly clear that to categorize microglia as resting or activated is simplistic, since the cells express a diverse array of receptors and therefore respond to an equally diverse array of ligands. Current evidence indicates that, like macrophages, microglia react differently to various stimuli. It is also simplistic to consider that microglia are a homogenous population of cells and emerging evidence indicates that there are probably regional differences. Microglia are unevenly distributed in the brain; in the mouse brain, microglial numbers are greater in grey matter than in white matter (Lawson et al., 1990) , but the opposite has been reported in human brain (Mittelbronn et al., 2001) . With respect to anatomical areas, overall microglial numbers are amongst the lowest in cerebellum of both mouse and human brain and highest in hippocampus of the mouse and medulla oblongata of the human (Lawson et al., 1990; Mittelbronn et al., 2001) . Interestingly, phenotypic differences have been observed in unstimulated microglial cultures prepared from different brain regions, with higher mRNA expression of tumour necrosis factor alpha (TNF), Fc gamma receptor and CD4 in microglia from hippocampus than other regions studied, including cortex and cerebellum (Ren et al., 1999) . This, and other findings, raise the possibility that resting state microglia are a heterogeneous population with subgroups of microglia assigned specific 'house-keeping' functions, as so eloquently discussed in a recent review (Hanisch, 2013) . The heterogeneity of microglia becomes more evident when cells shift from their resting state; for example, age-related changes in expression of different markers of microglial activation were found to be region-specific with the most profound changes in CD11b, CD68 and F4/80 observed in the cerebellum (Hart et al., 2012) .
Microglial activation

Resting microglia
The primary role of microglia under resting conditions is maintenance of homeostasis, neuroprotection and neurorepair, and repair, at least, is probably dependent on release of growth factors such as brain-derived neurotrophic factor (BDNF) and transforming growth factor (TGF)β . Time-lapse transcranial imaging of resting microglia showed that protrusion and retraction of processes is transient and occurs with high turnover. These processes make contact with astrocytes, neurons and blood vessels and sample the parenchyma every few hours. Tissue insult results in rapid recruitment of adjacent microglia and the appearance of spherical protrusions on their retracted processes, which is indicative of phagocytosis (Nimmerjahn et al., 2005) . Interestingly, microglial interaction with presynaptic terminals and dendritic spines is dependent on neuronal activity (Wake et al., 2009) .
What factors contribute to the maintenance of microglia in a resting state?
Resting microglia constitutively express surface receptors including complement receptors, Fc and CD4, and also CD200 and fractalkine receptors (CX3CR1) which are described as 'off signals' by Biber and colleagues in their review; these receptors engage with their respective ligands and help to maintain microglia in a quiescent state (Biber et al., 2007) . Whereas CD200 is widely distributed, CD200 receptor expression is confined to cells of the myeloid lineage; consequently co-culturing of neurons with microglia decreases lipopolysaccharide (LPS)-or amyloid-β (Aβ)-induced microglial activation and this is dependent on interaction of CD200 with its receptor (Lyons et al., 2007a; Lyons et al., 2009b) . The largely complementary expression of fractalkine on neurons and its receptor on microglia (Harrison et al., 1998) suggests an interaction similar to that described for CD200-CD200R, and evidence to support this has been reported (Cardona et al., 2006; Lyons et al., 2009a) . CD45 and signal regulatory protein (SIRP)1α, which are expressed predominantly on microglia, interact with neuronally expressed CD22 and CD47 respectively (Biber et al., 2007; Mott et al., 2004) . These interactions appear to function as 'off' signals as do secreted CD22 and fractalkine (Biber et al., 2007) , neurotrophins and anti-inflammatory cytokines such as interleukin (IL)-10 and IL-4 (Biber et al., 2007; Lyons et al., 2007b) . These factors attenuate changes induced in microglia by stimuli that include interferon- (IFN), LPS and Aβ (Clarke et al., 2008; Lyons et al., 2007b) and, interestingly, age-related decreases in expression of several of these 'off ' signals have been reported (Lyons et al., 2009a; Moore et al., 2007; Nolan et al., 2005) . 
Microglial activation is associated with decreased LTP
The importance of microglial activation in modulating neuronal function, particularly hippocampal function, has been recognized for decades since the first observations that IL-1 (and latterly other inflammatory cytokines), inhibit hippocampal-dependent learning, for example spatial learning (Oitzl et al., 1993 Gahtan and Overmier, 2001; Gibertini, 1998) , and contextual fear conditioning (Maier and Watkins, 1995; Pugh et al., 1998; . Indeed these reports post-date the recognition that IL-1 exerts an inhibitory effect on LTP in CA1 (Bellinger et al., 1993) , CA3 (Katsuki et al., 1990) and dentate gyrus in vitro (Cunningham et al., 1996) . These reports were followed by several others indicating similar inhibitory effects of IL-1 on LTP in vivo (Murray and Lynch, 1998) , and the acknowledgement that the inhibitory effect of LPS and age on LTP may be a consequence of increased hippocampal expression of IL-1 (Murray and Lynch, 1998) .
What is the basis of the inverse correlation between microglial activation and the deficit in LTP?
The most parsimonious explanation for the negative impact of A, LPS and age on LTP is that activated microglia release inflammatory mediators, including pro-inflammatory cytokines such as IL-1, IL-6 and TNF, which have been known for many years to impair LTP in vivo and in vitro as reviewed previously (Lynch, 2010) ; the extent of the change in LTP varies with preparation (in vivo vs in vitro), concentration and cytokine, although in most cases, induction of LTP is spared. Additionally, potent activators of microglia e.g. IFN, which induces release of inflammatory cytokines from microglia, also inhibit LTP (Kelly et al., 2013a) and interestingly this effect is blocked by the anti-inflammatory cytokine, IL-4 (Maher et al., 2006) .
The age-related increase in microglial activation, as indicated by expression of markers such as MHCII and CD68, appears to confer a susceptibility to inflammatory stimuli such that their effects on aged animals are more marked than on young animals. Specifically, an increase in production of inflammatory cytokines is reported to be coupled with deficits in hippocampal-dependent learning tasks (Barrientos et al., 2006; Chen et al., 2008) and enhanced microglial activation . A also induces a greater negative effect on LTP in aged, compared with young, rats and this is associated with an age-related increase in the effect of A on IL-1 concentration in the hippocampus .
Is there a link between astrocytic activation and LTP?
Microglial activation is often accompanied by that of astrocytes, for example in aged animals and APP/PS1 mice (Cowley et al., 2012; Gallagher et al., 2012; Gallagher et al., 2013; Kelly et al., 2013a) and astrocytes, like microglia, release inflammatory cytokines (Cowley et al., 2012) . Therefore, while there is a particularly strong link between microglial activation and LTP, the potential impact of astrocytic activation on LTP cannot be ignored. Indeed the critical role of astrocytes in controlling extracellular concentrations of neurotransmitters such as glutamate and GABA, as well as purines, by regulated uptake and release has been well described (Halassa et al., 2007) and these factors impact on LTP. Additionally, astrocytes modulate microglial activation. One possibility is that this may derive from the fact that astrocytes can release GABA, which activates GABA receptors expressed by microglia (Lee et al., 2011) . It is clear that astrocytes can also release inflammatory factors that trigger microglial activation and therefore contribute to the changes that occur as a consequence of chronic inflammation (Pascual et al., 2012; von Bernhardi and Ramirez, 2001 ). On the other hand, astrocytes secrete soluble factors including growth factors and anti-inflammatory cytokines (Eng et al., 2000) that decrease microglial activation. It has been shown that conditioned medium obtained from astrocytes decreased hydrogen peroxide (H 2 O 2 )-induced reactive oxygen species (ROS) production, increased expression and activity of the antioxidant enzyme, haemoxygenase-1, and decreased IFN-induced inducible iNOS expression in microglia (Min et al., 2006) . Astrocytes also modulate microglial activation by virtue of the fact that they express CD200 (Cox et al., 2013) ; indeed incubation of microglia with CD200-bearing astrocytic membrane preparations attenuates the LPS-induced increase in mRNA expression of IL-1, TNF and IL-6 and the LPS-induced release of TNF and IL-6 (Cox et al., 2013) .
Loss of 'off signals' is associated with microglial activation and deficits in LTP
The inverse relationship between microglial activation and synaptic plasticity has been linked with a decrease in expression of 'off' signals. For example, decreased expression of CD200, which occurs with age or following A treatment (Lyons et al., 2007a) , is associated with a poorer ability of animals to sustain LTP, and slices prepared from mice lacking CD200 also exhibit a deficit in LTP (Costello et al., 2011) . Interestingly, the deficit in LTP in aged animals is attenuated by CD200Fc (Cox et al., 2012) , whereas both the agerelated and A-induced decrease in LTP is at least partially reversed by IL-4 (Lyons et al., 2007b; Nolan et al., 2005) , which increases hippocampal expression of CD200 (Lyons et al., 2009b) . The age-related deficit in LTP and accompanying increase in microglial activation, are also associated with decreased hippocampal expression of fractalkine (Lyons et al., 2009a) and IL-10 ( Moore et al., 2007) . The relationship between neuroinflammation, particularly microglial activation, and impaired LTP, has been consolidated by the finding that strategies which attenuate microglial activation, including polyunsaturated fatty acids, statins or anti-inflammatory cytokines, also attenuate the loss of LTP (Adams et al., 1998) ; this is the case in a number of models in which LTP is decreased including in A-and LPStreated animals and in aged animals (Clarke et al., 2008; Clarke et al., 2007; Cowley et al., 2012; Kelly et al., 2001; Kelly et al., 2011; Nolan et al., 2005) . Figure 1 summarizes the factors that contribute to the age-related attenuation of LTP.
Figure 1. Proposed sequence leading to age-related decrease in LTP
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Age is associated with increased blood brain barrier permeability which, together with a chemotactic signal, increases infiltration of peripheral cells. These include NK and Th1 cells, which produce IFN, and this has a negative impact on LTP but also induces microglia, and probably astrocytes, to adopt the inflammatory M1 phenotype. These cells consequently increase production of inflammatory cytokines and reactive oxygen and nitrogen species which results in a loss of synaptic function and therefore LTP, while contributing to the existing neuroinflammation. In addition, age is associated with decreased expression of neuromodulatory molecules such as CD200 and fractalkine, which contribute to the maintenance of microglia in a quiescent state. This loss of control on microglia also permits increased production of inflammatory cytokines. It is proposed that a similar sequence of events occurs in models of Alzheimer's disease.
Microglial activation, A and LTP
A inhibits LTP
The ability of Aβ to induce microglial activation (Combs et al., 2001; Lyons et al., 2007b) and increase the expression and release of IL-1β and TNFα from microglia (Lyons et al., 2012; McQuillan et al., 2010) is well-documented. This might suggest that inflammatory changes are Aβ-driven (Hensley, 2010) , although this linear model is confounded by the finding that inflammatory cytokines increase APP processing (Blasko et al., 2000; Zhao et al., 2011) .
Several authors have reported that different forms of A have the capacity to inhibit LTP in vivo and in vitro. One of the earliest papers reported that central administration of A inhibited LTP in area CA1 of the hippocampus (Cullen et al., 1997 ) and this observation was followed by several others which indicated that synthetic and naturally-occurring A oligomers, including A-derived diffusible ligands, inhibited LTP in all major afferent pathways in the hippocampus both in vivo and in vitro (Koffie et al., 2011; Ondrejcak et al., 2010; Walsh et al., 2002) .
Although several groups have reported that acute Aβ treatment inhibits LTP (Freir et al., 2001; Klyubin et al., 2004; Minogue et al., 2003; Walsh et al., 2002) , fewer have examined the impact of chronic Aβ perfusion. However, it has been shown that LTP was decreased in CA1 in slices prepared from rats treated with Aβ for 10 days (Itoh et al., 1999) . Unpublished data from this laboratory have demonstrated that intracerebroventricular administration of Aβ 1-40 + Aβ 1-42 for 1 month induced microglial activation and inhibited LTP, with others showing that spatial learning was inhibited by infusion of Aβ 1-42 for 23 , 20 or 80 days (Nakamura et al., 2001) , Aβ 1-40 for 14 days (Nitta et al., 1997) or Aβ 1-40 + Aβ 1-42 for 1 or 2 months (Frautschy et al., 2001) .
The A-induced deficit in LTP in the dentate gyrus in vivo is associated with microglial activation and upregulation of inflammatory cytokines, with both the A-induced microglial activation and decreased LTP being attenuated by IL-4, the polyunsaturated fatty acid, eicosapentaenoic acid and the HMG-CoA reductase inhibitor, atorvastatin Lynch et al., 2007; Lyons et al., 2007b; Minogue et al., 2007) . Additionally, the A-induced inhibitory effect on LTP in CA1 in vitro was attenuated by pretreatment of slices with CD200Fc, which potently decreased the associated microglial activation (Lyons et al., 2012) .
Transgenic models of Alzheimer's disease and decreased LTP
There is no doubt that microglial activation and the accompanying neuroinflammatory changes are associated with neuronal deficits that characterize AD, but it is not known whether these changes drive the pathology and loss of neuronal function, or are a consequence of the pathological processes. Similarly, increased expression of markers of microglial activation is likely to be a unifying theme in the brain of all animal models of AD (Li et al., 2013) . One might predict that animal models would provide a clear indication of whether or not microglial activation drives the A accumulation or vice versa, however this has not been the case. A systematic examination of time-related changes in several parameters in 3 x Tg mice revealed that increased activation of microglia and astrocytes occurred at 2 months of age. This was accompanied by increased expression of human APP and limited co-staining of APP and Aβ, but it occurred in advance of any evidence of intracellular or extracellular staining of Aβ 1-42 . The authors suggested that these findings are consistent with a role for microglial activation in Aβ deposition. In a separate study, it was suggested that microglial activation contributed to the neuronal loss in these animals (Janelsins et al., 2008) . In contrast, albeit in a different model, APP/PS1 mice, microglial ablation appeared to have no effect on amyloidosis (Grathwohl et al., 2009) . In the same model, we found that mRNA expression of IL-1, CD68 and CD11b, as well as the numbers of CD11b + CD80 + and CD11b + MHCII + cells, were increased in brain tissue from 7-9 month-old APP/PS1 mice, and that this was accompanied by evidence of A accumulation (Gallagher et al., 2013; O'Reilly and Lynch, 2012) . In a separate study in 6 month-old APP/PS1 mice, we observed increases in concentrations of soluble and insoluble A 1-40 and A 1-42 but no increase in CD11b mRNA or in the number of CD11b + CD80 + or CD11b + CD86 + cells in the brain (McManus et al., 2014) . These studies have not provided a clear indication that microglial activation contributes to deposition of A, however several groups have reported that anti-inflammatory agents impact on A accumulation, and also on the associated loss of synaptic plasticity (Li et al., 2013) . A significant issue in the debate is the impact of an inflammatory microenvironment on phagocytic ability of microglia (and indeed macrophages). It has been reported that released inflammatory mediators and oxidative species from activated glia decrease phagocytic function (Hickman et al., 2008) ; others have similarly reported a negative impact of inflammatory mediators on microglial phagocytosis (Koenigsknecht and Landreth, 2004; Pan et al., 2011) . In contrast antiinflammatory cytokines, and microglia which adopt the M2 activation state, appear to facilitate phagocytosis (Hjorth et al., 2013; Koenigsknecht-Talboo and Landreth, 2005; Mandrekar-Colucci et al., 2012) .
The accumulating A burden, coupled with the associated microglial activation, appears to be irrevocably linked with a loss of synaptic plasticity in animals models of AD and, although it is not possible to identify the contribution of these factors separately, there is a great deal of evidence indicating that when the A burden is reduced, synaptic plasticity is restored, at least to some extent as reviewed previously (Li et al., 2013; Marchetti and Marie, 2011) . Among the first observations indicating that overexpression of APP, and the associated accumulation of A, affected LTP was a study which reported that the deficit in vivo and in vitro was accompanied by an impairment in spatial working memory in 15−17 month-old APP 695 SWE mice (Chapman et al., 1999) . Since that time, similar deficits in LTP and spatial learning have been described in other transgenic mouse models, including mice which overexpress APP and presenilin 1 (APP/PS1 mice) and 3 x Tg mice which overexpress APP, PS1 and tau, as described in a number of comprehensive reviews (Braidy et al., 2012; Marchetti and Marie, 2011) . While 6 month-old 3 x Tg mice exhibited a decrease in LTP in CA1, no change was observed in slices from 6 month-old APP/PS1 mice and it was suggested that the deficit was accounted for by an increase in intraneuronal Aβ (Oddo et al., 2003) . There is not complete agreement regarding the time at which changes in plasticity become apparent since there are reports of decreased LTP in APP/PS1 mice at 6 months (Marchetti and Marie, 2011) and even as early as 3 months of age (Trinchese et al., 2004) .
It is striking that many potential therapies have the ability to reduce A accumulation and neuroinflammatory changes in animal models of AD, and at least some of these have been shown to attenuate the loss of plasticity; these factors include immune therapies, antioxidants and modulators of glutamatergic, cholinergic and adrenergic receptor signalling and are comprehensively described in a recent review (Li et al., 2013) . Many impact on microglial function with evidence that acetylcholine and noradrenaline attenuate microglial activation (Carnevale et al., 2007) , an effect that is also attributed to activation of metabotropic glutamate receptor subtype 5 (Loane et al., 2009) . Interestingly, Aβ immunotherapy, in addition to decreasing the A burden, is capable of switching microglia into an activated phagocytic state (Koenigsknecht-Talboo et al., 2008; Wilcock et al., 2003; Wilcock et al., 2004) . Anti-inflammatory strategies which inhibit microglial activation have also been shown to be useful in attenuating some of the changes in models of AD, however although there is some evidence that long-term use of non-steroidal antiinflammatory treatment may reduce the risk of AD, no beneficial effect in prospective clinical trials has been reported (Boche and Nicoll, 2008) . There is, however, the caveat that if microglial activation is an event which triggers early changes, then treatment in established disease is unlikely to be especially advantageous.
Despite these promising pre-clinical leads, translation into clinical usefulness where deterioration of cognitive function is arrested or retarded, remains a challenge. Among the issues that need to be tackled is the ability of animal models to adequately reflect the full gamut of pathologies of AD and, in that context, identification of the triggers which precipitate the rapid loss of glial and neuronal function. Rational treatment strategies are likely to emanate from this, however the real key to successful treatment of AD is early diagnosis.
Conclusions
The negative impact of neuroinflammatory changes on neuronal function has been convincingly documented in the past decade or so and a key factor in driving neuroinflammation is glial activation, particularly activation of microglia. Although it is now accepted that microglia can adopt different activation states in response to diverse stimuli, in a manner somewhat analogous to macrophages, a great deal of work is necessary to gain a greater understanding of the functional phenotypes, the factors that control switching phenotypes in situ particularly in acute and chronic neuroinflammatory and/or neurodegenerative conditions, and the impact that switching might have on neuronal function.
